Ultragenyx up after US FDA approves gene therapy
17/09/2026 19:52
BUZZ-Ultragenyx up after US FDA approves gene therapy ** Ultragenyx Pharmaceutical RARE.O shares rise 7.3% to $13.84
** U.S Food and Drug Administration has approved Ultragenyx's gene therapy for the treatment of a rare, fatal disease
** Including session gains, stock has fallen ~40% YTD
(Reporting by Aatreyee Dasgupta)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx